886574-91-0

Basic information

• Product Name: Benzamide, 2-amino-4-fluoro-N-methoxy-N-methyl-
• CAS NO: 886574-91-0
• Molecular Formula: C9H11FN2O2
• Molecular Weight: 198.197
• Mol File: 886574-91-0.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Benzamide, 2-amino-4-fluoro-N-methoxy-N-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzamide, 2-amino-4-fluoro-N-methoxy-N-methyl-(886574-91-0)
• EPA Substance Registry System: Benzamide, 2-amino-4-fluoro-N-methoxy-N-methyl-(886574-91-0)

Safety Data

• Hazardous Substances Data: 886574-91-0(Hazardous Substances Data)

Upstream product

• 446-32-2 4-fluoroanthranilic acid 
• 1175134-33-4 N-methoxy-N-methyl-4-fluoro-2-nitro-benzamide 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 

Downstream Products

• 1175134-34-5 N-methoxy-N-methyl-4-fluoro-2-propylamino-benzamide 
• 1175134-49-2 N-methoxy-N-methyl-4-fluoro-2-ethylamino-benzamide 
• 1175134-51-6 N-methoxy-N-methyl-4-fluoro-2-n-butylamino-benzamide 
• 50817-53-3 (2-amino-4-fluorophenyl)(phenyl)methanone 

Relevant articles and documents

Catalytic Asymmetric Synthesis of Atropisomeric Quinolines through the Friedl?nder Reaction

A phosphoric acid catalyzed atroposelective Friedl?nder reaction was developed in which acetylacetone and a variety of 2′-substituted 2-Aminobenzophenones were successfully employed to give optically active biaryl quinolines in good yields and with high enantioselectivities.

NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

This present disclosure relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same. The present disclosure also provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, heart disease and so on.

Synthesis and evaluation of benzoxazinones as HIV-1 reverse transcriptase inhibitors. Analogs of Efavirenz (Sustiva(TM))

Two series of benzoxazinones differing in the aromatic substitution pattern were prepared and evaluated as HIV-1 reverse transcriptase inhibitors. The 5-fluoro (5a-d) and 6-nitro (5e-h) substituted compounds displayed activity comparable or better than Ef